WallStSmart

Health In Tech, Inc. Class A Common Stock (HIT)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 677% more annual revenue ($258.90M vs $33.33M). HIT leads profitability with a 3.8% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

HIT

Avoid

35

out of 100

Grade: F

Growth: 8.7Profit: 4.5Value: 5.7Quality: 5.0

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HITUndervalued (+62.4%)

Margin of Safety

+62.4%

Fair Value

$2.87

Current Price

$1.45

$1.42 discount

UndervaluedFair: $2.87Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HIT1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
53.1%10/10

Revenue surging 53.1% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

HIT4 concerns · Avg: 2.5/10
Market CapQuality
$98.29M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
3.8%3/10

3.8% margin — thin

P/E RatioValuation
75.0x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-1.16M2/10

Negative free cash flow — burning cash

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : HIT

The strongest argument for HIT centers on Revenue Growth. Revenue growth of 53.1% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : HIT

The primary concerns for HIT are Market Cap, Profit Margin, P/E Ratio. A P/E of 75.0x leaves little room for execution misses. Thin 3.8% margins leave little buffer for downturns.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

HIT is growing revenue faster at 53.1% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 35/100) and 43.0% revenue growth. HIT offers better value entry with a 62.4% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Health In Tech, Inc. Class A Common Stock

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Health In Tech, Inc. (HIT) is at the forefront of the digital health revolution, dedicated to enhancing healthcare delivery through innovative technology solutions. By harnessing advanced data analytics and proprietary software, HIT empowers healthcare providers and patients to make informed decisions, resulting in improved patient outcomes and operational efficiencies. The company's robust focus on compliance and cybersecurity uniquely positions it to thrive in the rapidly expanding digital health market. As the industry continues to evolve, HIT is poised to establish itself as a key player in advancing technology-driven healthcare solutions globally.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?